NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

National Research Council (US) and Institute of Medicine (US) Committee on Immunotherapies and Sustained-Release Formulations for Treating Drug Addiction; Harwood HJ, Myers TG, editors. New Treatments for Addiction: Behavioral, Ethical, Legal, and Social Questions. Washington (DC): National Academies Press (US); 2004.

Cover of New Treatments for Addiction

New Treatments for Addiction: Behavioral, Ethical, Legal, and Social Questions.

Show details


  1. Addis A, Moretti ME, Ahmed Syed F, Einarson TR, Koren G. Fetal effects of cocaine: An updated meta-analysis. Reproductive Toxicology. 2001;15(4):341–369. [PubMed: 11489591]
  2. Aoki K, Hirose Y, Kuroiwa Y. Immunoassay for methamphetamine with a new antibody. Forensic Science International. 1990;44:245–255. [PubMed: 2180798]
  3. Appelbaum PS, Grisso T. The MacArthur Treatment Competence Study. I: Mental illness and competence to consent to treatment. Law and Human Behavior. 1995;19(2):105–126. [PubMed: 11660290]
  4. Berke J, Hyman S. Addiction, dopamine, and the molecular mechanisms of memory [Review] Neuron. 2000;25(3):515–532. [PubMed: 10774721]
  5. Blaine JD, Ling W, Kosten TR, O'Brien CP, Chiarello RJ. Establishing the efficacy and safety of medications for the treatment of drug dependence and abuse: Methodological issues. In: Prien R, Robinson E, editors. Clinical evaluation of psychotropic drugs: Principles and guidelines. New York: Raven Press; 1994.
  6. Blower SM, Schwartz EJ, Mills J. Forecasting the future of HIV epidemics: The impact of antiretroviral therapies and imperfect vaccines. AIDS Reviews. 2003;5(2):113–125. [PubMed: 12876900]
  7. Byrnes-Blake KA, Carroll FI, Abraham P, Owens SM. Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats. International Immunopharmacology. 2001;1(2):329–338. [PubMed: 11360933]
  8. Carrera MR, Ashley JA, Wirsching P, Koob GF, Janda KD. A second-generation vaccine protects against the psychoactive effects of cocaine. Proceedings of the National Academy of Sciences; USA. 2001. pp. 1988–1992. [PMC free article: PMC29369] [PubMed: 11172063]
  9. Caulkins JP, Rydell CP, Schwabe W, Chiesa J. Mandatory minimum drug sentences: Throwing away the key or the taxpayers' money? Santa Monica, CA: RAND Corporation; 1997. (MR-827-DPRC)
  10. Center for Drug Evaluation and Research. CDER manual of policies and procedures. 2003. Available: http://www​ [November 6, 2003]
  11. Center for Substance Abuse Treatment. Changing the conversation: Improving substance abuse treatment—The National Treatment Plan Initiative. Rockville, MD: U.S. Department of Health and Human Services; 2000.
  12. Cerny EH, Levy R, Mauel J, Mpandi M, Mutter M, Henzelin-Nkubana C, Patiny L, Tuchscherer G, Cerny T. Preclinical development of a vaccine against smoking. Onkologie. 2002;2:406–411. [PubMed: 12415193]
  13. Chaloupka F, Pacula R. Economics and antihealth behavior: The economic analysis of substance use and misuse. In: Bickel W, Vuchinich R, editors. Reframing health behavior change with behavioural economics. Mahwah, NJ: Lawrence Erlbaum; 2000. pp. 89–111.
  14. Coffey RM, Mark T, King E, Harwood H, McKusick D, Genuardi J, Dilonardo J, Chalk M. National estimates of expenditures for substance abuse treatment, 1997. Rockville, MD: Center for Substance Abuse Treatment; 2001. (DHHS Publication No. SMA-01-3511)
  15. Cohen PH. Untreated addiction imposes an ethical bar to recruiting addicts for nontherapeutic studies of addictive drugs. Journal of Law, Medicine and Ethics. 2002;30(1):73–81. [PubMed: 11905272]
  16. D'Aunno T, Pollack HA. Changes in methadone treatment practices: Results from a national panel study, 1988-2000. Journal of the American Medical Association. 2002;288(7):850–856. [PubMed: 12186602]
  17. D'Aunno T, Vaughn M, McElroy P. An institutional analysis of HIV prevention efforts by the nation's outpatient drug abuse treatment units. Journal of Health and Social Behavior. 1999;40:175–192. [PubMed: 10467763]
  18. Demain AL. Small bugs, big business. The economic power of the microbe. Biotechnology Advances. 2000;18(6):499–514. [PubMed: 14538099]
  19. DeRenzo EG. The ethics of involving psychiatrically impaired persons in research. IRB: A Review of Human Subjects Research. 1994;16(6):7–9. [PubMed: 11659990]
  20. Devi CM, Bai MV, Lal AV, Umashankar PR, Krishnan LK. An improved method for isolation of anti-viper venom antibodies from chicken egg yolk. Journal of Biochemical and Biophysical Methods. 2002;51(2):129–138. [PubMed: 12062112]
  21. Dresser R. Mentally disabled research subjects: The enduring policy issues. Journal of the American Medical Association. 1996;276(1):67–72. [PubMed: 8667543]
  22. Ernst E. Second thoughts about safety of St. John's wort [published erratum in Lancet, 355, 580] Lancet. 1999;354(9195):2014–2016. [PubMed: 10636361]
  23. Farrelly MC, Bray JW, Zarkin GA, Wendling BW, Liccardo Pacula R. The effects of prices and policies on the demand for marijuana: Evidence from the National Household Surveys on Drug Abuse. Cambridge, MA: National Bureau of Economic Research; 1999. (Working Paper No. w6940)
  24. Ferguson L, Ries R, Russo J. Barriers to identification and treatment of hazardous drinkers as assessed by urban/rural primary care doctors. Journal of Addictive Diseases. 2003;22(2):79–90. [PubMed: 12703671]
  25. Flannery DJ, Williams LL, Vazsonyi AT. Who are they with and what are they doing? Delinquent behavior, substance use, and early adolescents' after-school time. American Journal of Orthopsychiatry. 1999;69(2):247–253. [PubMed: 10234390]
  26. Fox BS, Kantak KM, Edwards MA, Black KM, Bollinger BK, Botka AJ, French TL, Thompson TL, Schad VC, Greenstein JL, Gefter ML, Exley MA, Swain PA, Briner TJ. Efficacy of a therapeutic cocaine vaccine in rodent models. Nature Medicine. 1996;2(10):1129–1132. [PubMed: 8837612]
  27. Friedmann PD, Alexander JA, D'Aunno TA. Organizational correlates of access to primary care and mental health services in drug abuse treatment units. Journal of Substance Abuse Treatment. 1999;16(1):71–80. [PubMed: 9888124]
  28. Genevie L, Struening EL, Kallos JE, Geiler I, Muhlin GL, Kalplan S. Urban community reaction to health facilities in residential areas: Lessons from the placement of methadone facilities in New York City. International Journal of the Addictions. 1988;23(6):603–616. [PubMed: 3170049]
  29. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
  30. Greenstein RA, O'Brien CP, Woody G, Long M, Coyle G, Grabowski J, Vittor A. Naltrexone: A short-term treatment alternative for opiate dependence. American Journal of Drug and Alcohol Abuse. 1981;8(3):291–300. [PubMed: 7340503]
  31. Griesler PC, Kandel DB, Davies M. Ethnic differences in predictors of initiation and persistence of adolescent cigarette smoking in the National Longitudinal Survey of Youth. Nicotine and Tobacco Research. 2002;4(1):79–93. [PubMed: 11906684]
  32. Harwood H, Fountain D, Livermore G. The economic costs of alcohol and drug abuse in the United States, 1992-1998. Washington, DC: National Institute on Drug Abuse; 1998. (NIH Pub. No. 98-4327)
  33. Hieda Y, Keyler DE, Vandevoort JT, Kane JK, Ross CA, Raphael DE, Niedbalas RS, Pentel PR. Active immunization alters the plasma nicotine concentration in rats. Journal of Pharmacology and Experimental Therapeutics. 1997;283(3):1076–1081. [PubMed: 9399979]
  34. Hieda Y, Keyler DE, Ennifar S, Fattom A, Pentel PR. Vaccination against nicotine during continued nicotine administration in rats: Immunogenicity of the vaccine and effects on cocaine distribution to brain. International Journal of Immunopharmacology. 2000;22(10):809–819. [PubMed: 10963853]
  35. Institute of Medicine. Bridging the gap between practice and research: Forging partnerships with community-based drug and alcohol treatment. In: Lamb S, Greenlick MR, McCarty D, editors. Committee on Community-Based Drug Treatment. Washington, DC: National Academy Press; 1998. [PubMed: 25101381]
  36. Johnson BD, Rosenblum A, Kleber H. A new opportunity to expand treatment for heroin users in New York City: Public policy challenges for bringing buprenorphine into drug treatment programs and general medical practice. White Paper for New York City Department of Health and Mental Hygiene. 2003. Available: http://www​​/doh/pdf/public/dmh/whitepaper.pdf [August 21, 2003].
  37. Kabat GC. Fifty years' experience of reduced-tar cigarettes: What do we know about their health effects? Inhalation Toxicology. 2003;15(11):1059–1102. [PubMed: 12955615]
  38. Kantak KM, Collins SL, Bond J, Fox BS. Time course of changes in cocaine self-administration behavior in rats during immunization with the cocaine vaccine IPC-1010. Psychopharmacology. 2001;153(3):334–340. [PubMed: 11271406]
  39. Keyler DE, Hieda Y, St. Peter J, Pentel PR. Altered disposition of repeated nicotine doses in rats immunized against nicotine. Nicotine Tobacco Research. 1999;1:241–249. [PubMed: 11072421]
  40. Kirchmayer U, Davoli M, Verster A. The Cochrane Library. 1. Chichester, England: John Wiley & Sons; 2004. Naltrexone maintenance treatment for opioid dependence.
  41. Kleiman MAR. Costs and benefits of immunotherapies or depot medications for the treatment of drug abuse. In: Harwood HJ, Myers TG, editors. New treatments for addiction: Behavioral, ethical, legal, and social questions. Washington, DC: The National Academies Press; 2004. National Research Council and Institute of Medicine.
  42. Klein M. Research issues related to development of medications for treatment of cocaine addiction. Annals of the New York Academy of Sciences. 1998;844:75–91. [PubMed: 9668666]
  43. Klesges LM, Johnson KC, Somes G, Zbikowski S, Robinson L. Use of nicotine replacement therapy in adolescent smokers and nonsmokers. Archives of Pediatrics and Adolescent Medicine. 2003;157:517–522. [PubMed: 12796230]
  44. Kosten TR, Jalali B, Hogan I, Kleber HD. Family denial as a prognostic factor in opiate addict treatment outcome. Journal of Nervous and Mental Disease. 1983;171(10):611–616. [PubMed: 6619824]
  45. Kosten TR, Kranzler HR. What will we learn from the FDA clinical trials process and what will we still want to know about immunotherapies and depot medications to treat drug dependence? In: Harwood HJ, Myers TG, editors. New treatments for addiction: Behavioral, ethical, legal, and social questions. Washington, DC: The National Academies Press; 2004. National Research Council and Institute of Medicine.
  46. Kosten TR, Rosen M, Bond J, Settles M, Roberts JS, Shields J, Jack L, Fox B. Human therapeutic cocaine vaccine: Safety and immunogenecity. Vaccine. 2002a;20:1196–1204. [PubMed: 11803082]
  47. Kosten TR, Gonsa K, St. Clair Roberts J, Jack L, Bond J, Mitchell E, Fox B. Phase II human study of cocaine vaccine TA-CD; Paper prepared for the College on Problems of Drug Dependence Annual Meeting; June 8-13; Quebec City. 2002b.
  48. Kozlowski LT, Goldberg ME, Yost BA, Ahern FM, Aronson KR, Sweeney CT. Smokers are unaware of the filter vents now on most cigarettes: Results of a national survey. Tobacco Control. 1996;5(4):265–270. [PMC free article: PMC1759525] [PubMed: 9130359]
  49. Kozlowski LT, Goldberg ME, Yost BA, White EL, Sweeney CT, Pillitteri JL. Smokers' misperceptions of light and ultra-light cigarettes may keep them smoking. American Journal of Preventive Medicine. 1998;15(1):9–16. [PubMed: 9651633]
  50. Kranzler HR, Modesto-Lowe V, Nuwayser ES. Sustained-release naltrexone for alcoholism treatment: A preliminary study. Alcoholism, Clinical and Experimental Research. 1998;22:1074–1079. [PubMed: 9726277]
  51. Krystal JH, Cramer JA, Krol WF, Kirk GS, Rosenheck RA. Veterans Affairs Naltrexone Cooperative Study G. Naltrexone in the treatment of alcohol dependence. New England Journal of Medicine. 2001;345(24):1734–1739. [PubMed: 11742047]
  52. Lagrue G. Nicotine replacement therapy and smoking cessation: What choice for its status? Bulletin de l'Academie Nationale de Medecine. 1999;183(6):1175–1182. [PubMed: 10560171]
  53. Lawrance KG. Adolescent smokers' preferred smoking cessation methods. Canadian Journal of Public Health. 2001;92(6):423–426. [PubMed: 11799545]
  54. Lowinson JH, Payte JT, Joseph H, Marion IL, Dole VP. Methadone maintenance. In: Lowinson JH, Ruiz P, Milman RB, Langrod JG, editors. Substance abuse: A comprehensive textbook. Philadelphia: Williams and Wilkins; 1992. pp. 405–414.
  55. MacCoun R, Reuter P. Drug war heresies: Learning from other vices, times, and places. New York: Cambridge University Press; 2001.
  56. MacCoun RJ. Anticipating unintended consequences of vaccine-like immunotherapies for addictive drug use. In: Harwood HJ, Myers TG, editors. New treatments for addiction: Behavioral, ethical, legal, and social questions. Washington, DC: The National Academies Press; 2004. National Research Council and Institute of Medicine.
  57. Mallat SG, Ismail N. Plasmapheresis and related techniques: What should we know. Lebanese Medical Journal. 2002;50(1-2):45–49. [PubMed: 12841313]
  58. Mark TL, Coffey RM, King E, Harwood H, McKusick D, Genuardi J, Dilondardo J, Buck JA. Spending on mental health and substance abuse treatment, 1987-1997. Health Affairs. 2000;19(4):108–120. [PubMed: 10916964]
  59. McCrady BS, Bux DA. Ethical issues in informed consent with substance abusers. Journal of Consulting and Clinical Psychology. 1999;67(2):186–193. [PubMed: 10224728]
  60. McCuller WJ, Sussman S, Dent CW, Teran L. Concurrent prediction of drug use among high-risk youth. Addictive Behaviors. 2001;26(1):137–142. [PubMed: 11196288]
  61. McLellan AT, Lewis D, O'Brien CP, Kleber HD. Drug addiction as a chronic medical illness: Implications for treatment, insurance and evaluation. Journal of the American Medical Association. 2000;284(13):1689–1695. [PubMed: 11015800]
  62. Merton RK. The unanticipated consequences of purposive social action. American Sociological Review. 1936;1:894–904.
  63. Miller FH, Klanica K. Vaccines and immunotherapies to control addiction in minors: The legal framework. In: Harwood HJ, Myers TG, editors. New treatments for addiction: Behavioral, ethical, legal, and social questions. Washington, DC: The National Academies Press; 2004. National Research Council and Institute of Medicine.
  64. National Advisory Council on Alcohol Abuse and Alcoholism. Recommended council guidelines on ethyl administration in human experimentation. Washington, DC: National Institute on Alcohol Abuse and Alcoholism; 1988.
  65. National Advisory Council on Drug Abuse. Recommended guidelines for the administration of drugs to human subjects. Washington, DC: National Institute on Drug Abuse; 1997.
  66. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont report: Ethical principles and guidelines for the protection of human subjects of research. Washington, DC: U.S. Department of Health, Education, and Welfare; 1978. (Publication No. OS 78-0012) [PubMed: 25951677]
  67. National Research Council. Informing America's policy on illegal drugs: What we don't know keeps hurting us. Committee on Data and Research for Policy on Illegal Drugs. In: Mansiki CF, Pepper JV, Petrie CV, editors. Committee on Law and Justice and Committee on National Statistics. Commission on Behavioral and Social Sciences and Education. Washington, DC: National Academy Press; 2001.
  68. Nohria N, Gulati R. Is slack good or bad for innovation? Academy of Management Journal. 1995;39:716–725.
  69. O'Brien CP, Childress AR, Ehrman R, Robbins SJ. Conditioning factors in drug use: Can they explain compulsion? Journal of Psychopharmacology. 1998;12(1):15–22. [PubMed: 9584964]
  70. O'Connor PG, Samet JM. Substance abuse: The expanding role of general internal medicine. Journal of General Internal Medicine. 2002;17:398–399. [PMC free article: PMC1495043] [PubMed: 12047739]
  71. Office of National Drug Control Policy. The economic costs of drug abuse in the United States, 1992-1998. Washington, DC: Executive Office of the President; 2001. (Publication No. NCJ-190636) Available: http://www​.whitehousedrugpolicy​.gov/publications​/pdf/economic_costs98.pdf [August 21, 2003].
  72. O'Toole TP, Strain EC, Wand G, McCaul ME, Barnhart M. Outpatient treatment entry and health care utilization after a combined medical/substance abuse intervention for hospitalized medical patients. Journal of General Internal Medicine. 2002;17(5):334–340. [PMC free article: PMC1495041] [PubMed: 12047729]
  73. Owen P. The pros and cons of addiction medications. Hazelden Voice. 2002;7:3–12.
  74. Owens SM, Zorbas M, Lattin DL, Gunnell M, Polk M. Antibodies against arylcyclohexylamines and their similarities in binding specificity with the phencyclidine receptor. Journal of Pharmacology and Experimental Therapeutics. 1988;246:472–478. [PubMed: 2457075]
  75. Pentel PR. Vaccines and depot medications for drug addiction: Rationale, mechanisms of action, and treatment implications. In: Harwood HJ, Myers TG, editors. New treatments for addiction: Behavioral, ethical, legal, and social questions. Washington, DC: The National Academies Press; 2004. National Research Council and Institute of Medicine.
  76. Pentel PR, Keyler DE. Vaccination as a treatment for drug abuse: Nicotine, cocaine, phencyclidine. In: Levine MM, editor. New generation vaccines. New York: Marcel Dekker; 2004.
  77. Pentel PR, Malin DH, Ennifar S, Hieda Y, Keyler DE, Lake JR, Milstein JR, Basham LE, Coy RT, Moon JW, Naso R, Fattom A. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacology, Biochemistry, and Behavior. 2000;65:191–198. [PubMed: 10638653]
  78. Pierce J, Farkas A, Evans N. Tobacco use in California 1992: A focus on preventing uptake in adolescents. Sacramento: California Department of Human Services; 1993.
  79. Plessinger MA. Prenatal exposure to amphetamines: Risks and adverse outcomes in pregnancy. Obstetrics and Gynecology Clinics of North America. 1998;25:119–138. [PubMed: 9547763]
  80. Price JH, Yingling F, Dake JA, Telljohann SK. Adolescent smoking cessation services of school-based health centers. Health Education and Behavior. 2003;30(2):196–208. [PubMed: 12693523]
  81. Proksch JW, Gentry WB, Owens SM. Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats. Journal of Pharmacology and Experimental Therapeutics. 2000;292(3):831–837. [PubMed: 10688594]
  82. Rawson RA, McCann MJ, Hasson AJ, Ling W. Addiction pharmacotherapy 2000: New options, new challenges. Journal of Psychoactive Drugs. 2000;32:371–378. [PubMed: 11210198]
  83. Ridgely MS, Iguchi MY, Chiesa J. The use of immunotherapies and sustained-release formulations in the treatment of drug addiction: Will current law support coercion? In: Harwood HJ, Myers TG, editors. New treatments for addiction: Behavioral, ethical, legal, and social questions. Washington, DC: The National Academies Press; 2004. National Research Council and Institute of Medicine.
  84. Robinson TE, Berridge KC. The psychology and neurobiology of addiction: An incentive-sensitization view. Addiction. 2000;95(Suppl 2):S91–S118. [PubMed: 11002906]
  85. Sagberg F, Fosser S, Saetermo IA. An investigation of behavioural adaptation to airbags and antilock brakes among taxi drivers. Accident, Analysis and Prevention. 1997;29(3):293–302. [PubMed: 9183467]
  86. Sargent JD, Mott LA, Stevens M. Predictors of smoking cessation in adolescents. Archives of Pediatrics and Adolescent Medicine. 1998;152(4):388–393. [PubMed: 9559717]
  87. Shimm DS, Speece RG. Rate of refusal to participate in clinical trials. IRB: A Review of Human Subjects Research. 1992;14:7–9. [PubMed: 11651246]
  88. Shoeman D, Keyler DE, Pentel P. Vaccination of female rats against nicotine reduces nicotine distribution to fetal brain (abstract); Paper presented at the Society for Research on Nicotine and Tobacco Annual Meeting; Savannah, GA. 2002.
  89. Sieber JE. Ethical considerations in planning and conducting research on human subjects. Academic Medicine. 1994;68(Suppl 9):9–13. [PubMed: 8373498]
  90. Simister NE, Story CM. Human placental Fc receptors and the transmission of antibodies from mother to fetus. Journal of Reproductive Immunology. 1997;37:1–23. [PubMed: 9501287]
  91. Simoes EA, Groothuis JR. Respiratory syncytial virus prophylaxis—the story so far. Respiratory Medicine. 2002;96(Suppl B):S15–S24. [PubMed: 11996400]
  92. Smith MD. Antibody production in plants. Biotechnology Advances. 1996;14(3):267–281. [PubMed: 14537156]
  93. Sobeck J, Abbey A, Agius E, Clinton M, Harrison K. Predicting early adolescent substance use: Do risk factors differ depending on age of onset? Journal of Substance Abuse. 2000;11(1):89–102. [PubMed: 10756516]
  94. Stein MD, Friedman PD. Generalist physicians and addiction care: From turfing to sharing the turf. Journal of the American Medical Association. 2001;286:1764–1765. [PubMed: 11594904]
  95. Sturm R, Goldman W, McCulloch J. Mental health and substance abuse parity: A study of Ohio's state employee program. Journal of Mental Health Policy and Economics. 1998;1(3):129–134. [PubMed: 11971152]
  96. Substance Abuse and Mental Health Services Administration. National Survey of Substance Abuse Treatment Services (N-SSATS): 2000 data on substance abuse treatment facilities. Rockville, MD: Author; 2002. (Rep. No. DASIS Series: A-16; DHHS Publication No. SMA 02-3668)
  97. Substance Abuse and Mental Health Services Administration. The DAWN report: Trends in drug-related emergency department visits, 1994-2001 at a glance. 2003. Available: http://dawninfo​.samhsa​.gov/pubs_94_02/shortreports​/files/TDR​_EDvisits_glance_1994_2001.pdf [November 7, 2003].
  98. Swarns RL. Giuliani orders 5 city hospitals to wean addicts off methadone. New York Times. 1998 August 15
  99. Terada K, Niizuma T, Ogita S, Kataoka N. Responses of varicella zoster virus (VZV)-specific immunity in seropositive adults after inhalation of inactivated or live attenuated varicella vaccine. Vaccine. 2002;20(31-32):3638–3643. [PubMed: 12399190]
  100. Thomas CP. Dissertation. Brandeis University; 2000. No magic bullet: Adoption of naltrexone by clinical providers.
  101. Thomas CP, McCarty D. Adoption of drug treatment technology in specialty and primary care settings. In: Harwood HJ, Myers TG, editors. New treatments for addiction: Behavioral, ethical, legal, and social questions. Washington, DC: The National Academies Press; 2004. National Research Council and Institute of Medicine.
  102. Thomas CP, Walack S, Lee SS, McCarty D, Swift R. Research to practice: Factors affecting the adoption of naltrexone in alcoholism treatment. Journal of Substance Abuse Treatment. 2003;24:1–11. [PubMed: 12646325]
  103. Thorndike AN, Biener L, Rigotti NA. Effect on smoking cessation of switching nicotine replacement therapy to over-the-counter status. American Journal of Public Health. 2002;92(3):437–442. [PMC free article: PMC1447095] [PubMed: 11867326]
  104. Tuncok Y, Hieda Y, Keyler DE, Brown S, Ennifar S, Fattom A, Pentel PR. Inhibition of nicotine-induced seizures in rats by combining vaccination against nicotine with chronic nicotine infusion. Experimental and Clinical Psychopharmacology. 2001;9(2):228–234. [PubMed: 11518099]
  105. U.S. Department of Health and Human Services. Treating tobacco use and dependence. Washington, DC: U.S. Public Health Service; 2000.
  106. Villamor N. Mechanism of action and resistance to monoclonal antibody therapy. Seminars in Oncology. 2003;30(4):424–433. [PubMed: 12939711]
  107. Vizcarra C. New perspectives and emerging therapies for immune-mediated inflammatory disorders. Journal of Infusion Nursing. 2003;26(5):319–325. [PubMed: 14506365]
  108. von Sydow K, Lieb R, Pfister H, Hofler M, Wittchen HU. What predicts incident use of cannabis and progression to abuse and dependence? A 4-year prospective examination of risk factors in a community sample of adolescents and young adults. Drug and Alcohol Dependence. 2002;68(1):49–64. [PubMed: 12167552]
  109. Weissman M. Stigma. Journal of the American Medical Association. 2001;285:261–262. [PubMed: 11176821]
  110. Wilson B. Alcoholics Anonymous: The story of how many thousands of men and women have recovered from alcoholism. New York: Alcoholics Anonymous; 1955.
  111. Woody GE. Treating dually diagnosed patients. Psychiatric Times. 2003;20(1):29–30.
  112. Woody GE, McNichols L. Putting addiction treatment medications to use: Lessons learned. In: Harwood HJ, Myers TG, editors. New treatments for addiction: Behavioral, ethical, legal, and social questions. Washington, DC: The National Academies Press; 2004. National Research Council and Institute of Medicine.
  113. World Health Organization. The history of vaccination. 2003. Available: http://www​​/history/history.shtml [November 5, 2003].
Copyright © 2004, National Academy of Sciences.
Bookshelf ID: NBK24626


  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (6.7M)

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...